The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load

Journal of Cardiology

Volumn 60, Issue 5, 2012, Pages 395-400

  Hiramitsu, Shinya ^a   Miyagishima, Kenji ^b   Ishii, Junichi ^c   Matsui, Shigeru ^b   Naruse, Hiroyuki ^b   Shiino, Kenji ^b   Kitagawa, Fumihiko ^c   Ozaki, Yukio ^b  

^a Hiramitsu Heart Clinic   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ezetimibe; Insulin resistance; Insulin sensitivity; Obesity; Postprandial dyslipidemia

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B48; EZETIMIBE; FAT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; DRUG EFFECT; DYSLIPIDEMIA; FAT INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; POSTPRANDIAL STATE; WAIST CIRCUMFERENCE;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-48; AZETIDINES; BLOOD GLUCOSE; DIETARY CARBOHYDRATES; DIETARY FATS; GLUCOSE; HUMANS; HYPERLIPIDEMIAS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; TIME FACTORS; TRIGLYCERIDES; YOUNG ADULT;

EID: 84868619241     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.07.010     Document Type: Article

References (19)

1. National Nutrition & Health Survey 1998, Ministry of Health, Labour and Welfare, Tokyo.
2. Kubo M., Kiyohara Y., Kato I., Tanizaki Y., Arima H., Tanaka K., Nakamura H., Okubo K., Iida M. Trend in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003, 34:2349-2354.
3. Tanaka A. Postprandial hyperlipidemia and atherosclerosis. J Atheroscler Thromb 2004, 11:322-329.
4. Maggi F.M., Raselli S., Grigore L., Redaelli L., Fantappiè S., Catapano A.L. Lipoprotein remnants and endothelial dysfunction in the postprandial phase. J Clin Endocrinol Metab 2004, 89:2946-2950.
5. Iso H., Naito Y., Sato S., Kitamura A., Okamura T., Sankai T., Shimamoto T., Iida M., Komachi Y. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 2001, 153:490-499.
6. Eberly L.E., Stamler J., Neaton J.D. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003, 163:1077-1083.
7. Altmann S.W., Davis H.R., Zhu L., Yao X., Hoos L.M., Tetzloff G., Iyer S.P.N., Maguire M., Golovko A., Zeng M., Wang L., Murgolo N., Graziano M.P. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:1201-1204.
8. Saito Y., Yamada N., Nakatani N., Teramoto T., Oikawa S., Yamashita S., Tsushima M., Nakashima M., Yamamoto A. Phase III clinical study of ezetimibe - double-blind comparative study with cholestimide. J Clin Therap Med 2007, 23:493-522.
9. Hiramitsu S., Ishiguro Y., Matsuyama H., Yamada K., Kato K., Noba M., Uemura A., Yoshida S., Matsubara Y., Kani A., Hasegawa K., Hishida H., Ozaki Y. The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. J Atheroscler Thromb 2010, 17:106-114.
10. Deushi M., Nomura M., Kawakami A., Haraguchi M., Ito M., Okazaki M., Ishii H., Yoshida M. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007, 581:5664-5670.
11. Masuda D., Nakagawa-Toyama Y., Nakatani K., Inagaki M., Tsubakio-Yamamoto K., Sandoval J.C., Ohama T., Nishida M., Ishigami M., Yamashita S. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009, 39:689-698.
12. Harris M., Davis W., Brown W.V. Ezetimibe. Drugs Today 2003, 39:229-247.
13. Uemura Y., Watarai M., Ishii H., Koyasu M., Takemoto K., Yoshikawa D., Shibata R., Matsubara T., Murohara T. Atorvastatin 10mg plus ezetimibe 10mg compared with atorvastatin 20mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol 2012, 59:50-56.
14. Nakamura T., Hirano M., Kitta Y., Daisuke F., Saito Y., Kawabata K., Obata J., Watanabe Y., Watanabe K., Kugiyama K. A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. J Cardiol 2012, [Epub ahead of print].
15. Tremblay A.J., Lamarche B., Hogue J.C., Couture P. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J Lipid Res 2009, 50:1463-1471.
16. Nomura M., Ishii H., Kawakami A., Yoshida M. Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance. Am J Physiol Endocrinol Metab 2009, 297:E1030-E1038.
17. Labonté E.D., Camarota L.M., Rojas J.C., Jandacek R.J., Gilham D.E., Davies J.P., Ioannou Y.A., Tso P., Hui D.Y., Howles P.N. Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice. Am J Physiol Gastrointest Liver Physiol 2008, 295:G776-G783.
18. Yoneda M., Fujita K., Nozaki Y., Endo H., Takahashi H., Hosono K., Suzuki K., Mawatari H., Kirikoshi H., Inamori M., Saito S., Iwasaki T., Terauchi Y., Kubota K., Maeyama S., et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol Res 2010, 40:613-621.
19. Chan D.C., Watts G.F., Gan S.K., Ooi E.M., Barrett P.H. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010, 33:1134-1139.